|
Jun 5
|
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
|
|
May 31
|
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
|
|
May 30
|
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?
|
|
May 30
|
Arvinas to Present at Jefferies Global Healthcare Conference
|
|
May 29
|
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
|
|
Apr 28
|
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
|
|
Apr 28
|
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
|
|
Apr 23
|
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 21
|
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
|
|
Mar 27
|
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
|
|
Mar 14
|
Biotech Alert: Searches spiking for these stocks today
|
|
Mar 14
|
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
|
|
Mar 13
|
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
|
|
Mar 13
|
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
|
|
Mar 12
|
Arvinas' Vepdegestrant Likely to Have 'Restricted Label' in Breast Cancer, Wedbush Says
|
|
Mar 12
|
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
|
|
Mar 11
|
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
|
|
Mar 11
|
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
|
|
Mar 11
|
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
|
|
Mar 11
|
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
|